A study using an app to help people having treatment for neuroendocrine tumours
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is looking at a mobile application (app) for people to report their symptoms and how they are feeling during treatment.
More about this trial
Researchers have developed an app for people having treatment for neuroendocrine tumours.
The purpose of this app is to help people during their treatment. It allows them to report symptoms to their hospital team. And it allows the hospital team to record how people are feeling and if there are any changes in their quality of life following treatment.
You use the mobile application to:
- report any symptoms you are having
- report side effects of treatment
- report how you’ve been feeling (
quality of life 
) - keep a record of hospital appointments
The information in the app is analysed. The healthcare team can see your answers on the system. If necessary, they can message you through the app or contact you via email or phone. The app also provides links to online resources for education and support.
The main aims of the study are to:
- check if it’s possible to monitor symptoms via the app
- see if people think the app is useful
- see if people use it to complete the quality of life questionnaires
Who can enter
The following bullet points are a summary of the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this study if all of the following apply. You:
- have a neuroendocrine tumour and are due to have treatment. The treatment may include chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor radionuclide therapy (PRRT), embolization treatments, ablative treatment or surgery. We have information about these treatments for NETs.
- can speak and understand English
- are at least 18 years old
Who can’t take part
You cannot join this study if any of these apply. You:
- have another cancer that you are having treatment for
- don’t have a smartphone or tablet
- may have problems understanding the questionnaires and how to complete them
- have a mental health problem that the study team think could affect you taking part
Trial design
The study team need 2,000 people to take part.
You download the application from your mobile device app store onto your phone or tablet.
You report your symptoms on the app each day. There are daily alerts to remind you to do this. The length of time that you report these symptoms varies according to which treatment you are having. The study team can tell you more about this.
You also complete 6 quality of life questionnaires. The team may call these PROMs. This stands for patient reported outcome measures. Researchers use PROMs to assess how people are feeling, and how they rate their quality of life. You do these on the app:
- when you join the study
- at 1 month and then
- every 3 months for 1 year
Hospital visits
You don’t have any extra hospital visits if you take part in this trial.
Side effects
The researchers don’t think you will have any extra side effects if you take part in this study. However answering questions about any symptoms you may have, could cause you to think more about them.
The information you provide is stored electronically. All the information you provide is . It won’t be possible to identify you in any results from the study.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Rajaventhan Srirajaskanthan
Supported by
King’s College Hospital NHS Foundation Trust (KCH)
Imaging Equipment Limited
Neuroendocrine Cancer UK
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
Last reviewed:
Dangoor Education since 2010.
